Storys zum Thema Pharma

MSD Merck Sharp & Dohme AG

MSD in Switzerland launches new gender-neutral parental leave policy effective February 1st, 2020

Lucerne (ots) - Following its nomination for an eight time in a row as Top Employer Switzerland, MSD (Merck Sharp & Dohme AG) is delighted to announce the introduction of a new gender-neutral parental leave policy to all its employees within ...

MSD Merck Sharp & Dohme AG

On World Cancer Day, MSD Switzerland Stands United in Support of its Patients

Lucerne (ots) - World Cancer Day every 4th of February is a global uniting movement led by the Union for International Cancer Control (UICC). MSD (Merck Sharp & Dohme) is a proud sponsor of this initiative, joining the conversation to create a groundswell of awareness and action that will enable powerful ...

MSD Merck Sharp & Dohme AG

Swissmedic grants approval for pembrolizumab (KEYTRUDA®) in combination with axitinib (Inlyta®) for first-line therapy of advanced renal cell carcinoma(1)

Lucerne (ots) - - Swissmedic approval is based on a significant benefit in overall survival with pembrolizumab in combination with axitinib compared to sunitinib in the Phase III study KEYNOTE-426 - Pembrolizumab is the first PD-1 inhibitor that has ...

Debiopharm International SA

Novadiscovery raises series A financing to scale its in silico clinical trial platform - Debiopharm leads the round with EUR 5 million

Lausanne (ots) - - Novadiscovery pioneers the use of in silico clinical trials to predict drug efficacy and optimize clinical development, an approach meeting the strong expectations from pharmaceutical companies for faster and more efficient development, and benefiting from increased endorsement from health ...

Debiopharm International SA

Knight Partners with Debiopharm for the Commercialization of Trelstar® in Canada

MONTREAL, CANADA and LAUSANNE, SWITZERLAND (ots) - Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company and Debiopharm, a swiss-based, global biopharmaceutical company, today announced that they have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada. ...

ForaCare Suisse AG

ForaCare Suisse AG Launches "Lab in the Pocket" Technology

ST. GALLEN, Switzerland (ots) - Innovative FORA 6 GTel Capability Provides 6 Tests with Single Device, SIM Direct-to-Telehealth Connectivity ForaCare Suisse AG announced the launch of its FORA 6 GTel multi-functional monitoring device with its new "Lab in the Pocket" technology (available on the GTel model and FORA 6 Series products). The innovative 6-in-1 monitoring technology provides seamless 3G/4G data transmission of ...

Helsana Gruppe

Quality-related problems concerning the prescription of medication / Helsana Drug Report

Zurich (ots) - The medication costs in Switzerland amounted to about CHF 7.6 billion in 2018. Since 2010, costs have risen by 46 percent, whereby half of this increase was attributable to immunosuppressants and cancer medication. Great savings potential is above all associated with the use of biosimilars. One of the other findings of this year's Helsana Drug Report is ...

CROMA-PHARMA GmbH

Croma-Pharma GmbH expands its portfolio introducing elureTM / Croma complements its skincare portfolio with the advanced skin brightening solution elureTM.

Leobendorf (ots) - Croma is always committed to deepening its product portfolio to support customers in their daily work. With the acquisition of elure's distribution rights in its strategic markets, Croma can now offer an attractive new skincare that specifically addresses hyperpigmentation with a unique mode of ...

Versameb AG

Versameb raises CHF 6.4 million in Seed C round and strengthens the team

Debiopharm International SA

A pancreatic and colorectal cancer trial initiated to address the needs of patients with Immune Checkpoint Inhibitor-resistant disease by combining IAP antagonist Debio 1143 with Keytruda®

Lausanne (ots) - First patient enrolled in the investigator initiated CATRIPCA study (Combination with an IAP Antagonist To Reverse Immune resistance in Pancreatic and Colorectal Adenocarcinoma) at the Léon Bérard Cancer Center in Lyon France Debiopharm (www.debiopharm.com) announced today the first patient ...

Debiopharm International SA

Debiopharm successfully completes randomized Phase II study for IAP antagonist Debio 1143 in high risk head & neck cancer patients

Lausanne, Switzerland (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced positive topline results across clinical endpoints following the completion of the two-year follow-up period of its double-blind, randomized Phase II study of Debio 1143 in high-risk, previously untreated ...

Debiopharm International SA

Debiopharm and BIOASTER join forces to expand research to combat infectious diseases

Lausanne, Switzerland and Lyon, France (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, and BIOASTER (www.bioaster.org), the French Technology Research Institute in infectiology and microbiology, announced today having officialized a broad research agreement for the development of diagnostic and management innovation for infectious diseases. ...

Debiopharm International SA

Debiopharm expands its Immuno-Oncology development program for Debio 1143, with the first IAP inhibitor/nivolumab combination trial

Lausanne, Switzerland (ots) - First patient enrolled in SMARTPLUS-106, a Phase lb/II study in patients failing prior PD-1/PD-L1 treatment in selected solid tumors Debiopharm (www.debiopharm.com) announced today the first patient enrolled in SMARTPLUS-106, an exploratory study investigating the safety and efficacy of ...

Swiss Medtech

Medical technology sector suffers from legal uncertainty / Swiss Medtech gives recommendation to Swiss medical device manufacturers

Micreos

Micreos Raises EUR30 Million for Endolysin Technology Set to Replace Antibiotics / Funding for clinical development program XZ.700 and Gladskin Eczema USA launch

THE HAGUE, Netherlands (ots) - Dutch biotechnology company Micreos announced it has secured EUR30 million in funding to accelerate the development of its endolysin technology, set to replace antibiotics. Proceeds are earmarked for the clinical development program of its endolysin XZ.700 and the USA launch of its ...

Debiopharm International SA

GenePOC obtains FDA clearance for its GenePOC(TM) Strep A test in the US

Québec, Canada (ots) - GenePOC Inc., member of the Debiopharm Group, announces its third test to be cleared by the FDA, the GenePOC Strep A assay, to be used with the revogene(TM) device. About Group A Streptococcus (GAS) infection GAS is the most common bacterial etiology of pharyngitis accounting for 15 to 30% cases in children and 5 to 20% in adults[1]. In the ...

ForaCare Suisse AG

2

ForaCare Suisse AG forms service-oriented partnership with B. Braun

Debiopharm International SA

Debiopharm Group regains the commercial rights to Trelstar® (Triptorelin pamoate) and looks for new partners in North America

Lausanne, Switzerland (ots) - Debiopharm and Allergan agree to transition the rights to commercialize Trelstar to new licensees. Debiopharm is in advanced discussion with a potential partner in Canada and is engaged in a bidding process for US rights. Debiopharm Group(TM) (Debiopharm - www.debiopharm.com), a ...

De Micco & Friends SL

EUR 500 M class action lawsuit against NOLOTIL painkiller manufacturer Boehringer and distributers / International press conference, Barcelona, 28th November 2018

Barcelona (ots) - The medication NOLOTIL is one of the most widely distributed painkillers worldwide. However, its use has been prohibited in some countries because of adverse side-effects. To this day, NOLOTIL is still prescribed for acute pain in Spain, despite the potentially severe side-effects. The incidence of ...

roelli roelli confectionery schweiz GmbH

2

Cannabis: now available as a chewing gum

Grünenthal Gruppe

Grünenthal Initiates Pivotal Phase III Trials in Complex Regional Pain Syndrome

Aachen, Germany (ots) - Grünenthal announced today that first patients have been enrolled in two trials of the company's pivotal phase III program investigating neridronate for the treatment of Complex Regional Pain Syndrome (CRPS). These two trials, KF7013-02 and KF7013-04, are investigating the efficacy and safety of neridronate in 360 patients with CRPS. ...

IMI-PainCare

IMI-PainCare: Public-private partnership tackles major challenges in the care of pain patients

Aachen (ots) - To improve the care of patients with acute or chronic pain, a consortium from academia, small and medium-sized enterprises (SMEs), pain societies, patient organizations and pharmaceutical industry launched the research project "IMI-PainCare - Improving the care of patients suffering from acute or ...

Sequana Medical AG

Sequana Medical announces inclusion of alfapump® in EASL Clinical Practice Guidelines and presentation of study demonstrating physical component of QOL is predictor of mortality in refractory ascites

Zurich (ots) - Sequana Medical AG ("Sequana Medical"), a commercial stage medical device company and an innovator in the management of liver disease & malignant ascites, announces two important developments at the recent EASL (European Association for the Study of the Liver) International Liver Congress 2018. First, ...

Debiopharm International SA

Debiopharm continues the fight against antibiotic resistance with investment in ABAC Therapeutics Inc. / ABAC develops new targeted antibiotics for patients with severe infections

Lausanne (ots) - Debiopharm Group (TM) announces an investment in antibiotic development with the acquisition of a minority stake in ABAC Therapeutics Inc. This investment was made through the Debiopharm Innovation Fund, its strategic investment fund, and illustrates the synergy between the group companies in the ...